Gene therapy shows promise for reversing blindnessScience DailyIn a laboratory study in Oxford, researchers have shown how it might be possible to reverse blindness using gene therapy to reprogram cells at the back of the eye to become light sensitive… Continue reading
|
Celsion’s Immunotherapy Candidate Impresses, Stock Surges
Nasdaq Celsion CorporationCLSN announced results from phase Ib study – OVATION – evidently showing biological activity of its immunotherapy candidate, GEN1, in advanced ovarian cancer patients. Celsion is developing the candidate for newly diagnosed … |
KQED |
Spinal Patients Continue Remarkable Recovery After Stem Cell Injections, Company Says
KQED Patients with spinal injuries have continued to heal long after they’ve received an initial injection of stem cells, according to data released Oct. 2 by the biotech company conducting a clinical trial on the treatment. ‘The rate of recovery at 12 … |
Labiotech.eu (blog) |
Celyad: First “Clinical Validity” For NKR CAR T-Cells
Investing.com Celyad SA (NASDAQ:CYAD) has reported a complete morphological leukaemia-free status (MFLS) response in acute myeloid leukaemia (AML) in the NKR CAR T-cell THINK study. Given that spontaneous remission in refractory/relapsed AML is extremely … Belgian Biotech’s Leukemia CAR–T Treatment Leaves Patient Cancer-FreeLabiotech.eu (blog) |
|
Celsion’s Immunotherapy Candidate Impresses, Stock Surges
Zacks.com Celsion Corporation (CLSN – Free Report) announced results from phase Ib study — OVATION — evidently showing biological activity of its immunotherapy candidate, GEN1, in advanced ovarian cancer patients. Celsion is developing the candidate for newly … |